Skip to content
Lansoprazole
Prevacid, Prevpac (lansoprazole) is a small molecule pharmaceutical. Lansoprazole was first approved as Prevacid on 1995-05-10. It is used to treat duodenal ulcer, esophagitis, gastroesophageal reflux, helicobacter infections, and stomach ulcer amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
digestive system diseasesD004066
Trade Name
FDA
EMA
Prevacid (generic drugs available since 2009-11-10)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amoxicillin
+
Clarithromycin
+
Lansoprazole
Tradename
Company
Number
Date
Products
PREVPAC (COPACKAGED)TakedaN-050757 DISCN1997-12-02
1 products, RLD
Hide discontinued
Lansoprazole
Tradename
Company
Number
Date
Products
LANSOPRAZOLEDexcel PharmaN-208025 OTC2016-06-07
1 products
PREVACID 24 HRPerrigoN-022327 OTC2009-05-18
1 products, RLD, RS
PREVACIDTakedaN-020406 RX1995-05-10
1 products, RLD, RS
PREVACIDTakedaN-021428 RX2002-08-30
2 products, RLD, RS
Show 3 discontinued
Lansoprazole
+
Naproxen
Tradename
Company
Number
Date
Products
PREVACID NAPRAPAC 250 (COPACKAGED)TakedaN-021507 DISCN2003-11-14
1 products, RLD
PREVACID NAPRAPAC 375 (COPACKAGED)TakedaN-021507 DISCN2003-11-14
1 products
PREVACID NAPRAPAC 500 (COPACKAGED)TakedaN-021507 DISCN2003-11-14
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
lansoprazoleANDA2023-06-21
prevacid 24 hrNew Drug Application2023-03-30
prevpacNew Drug Application2010-03-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
duodenal ulcerEFO_0004607D004381K26
esophagitisHP_0100633D004941K20
gastroesophageal refluxEFO_0003948D005764K21
helicobacter infectionsEFO_1000961D016481
stomach ulcerD013276K25
zollinger-ellison syndromeD015043E16.4
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Lansoprazole, Lansoprazole, Dexcel
110770552036-04-21DP
ATC Codes
A: Alimentary tract and metabolism drugs
A02: Drugs for acid related disorders
A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
A02BC: Proton pump inhibitors for peptic ulcer and gord
A02BC03: Lansoprazole
A02BC53: Lansoprazole, combinations
A02BD: Combinations for eradication of helicobacter pylori
A02BD02: Lansoprazole, tetracycline and metronidazole
A02BD03: Lansoprazole, amoxicillin and metronidazole
A02BD07: Lansoprazole, amoxicillin and clarithromycin
A02BD09: Lansoprazole, clarithromycin and tinidazole
A02BD10: Lansoprazole, amoxicillin and levofloxacin
HCPCS
No data
Clinical
Clinical Trials
111 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative painD010149G89.182454115
PainD010146EFO_0003843R52135211
CataractD002386EFO_0001059H26.92428
Macular edemaD0082692237
AnesthesiaD000758213
OsteoarthritisD010003EFO_0002506M15-M19123
Migraine disordersD008881EFO_0003821G431113
ArthritisD001168EFO_0005856M05-M1422
Rotator cuff injuriesD000070636M75.111
OsteonecrosisD010020EFO_0004259M8711
Show 22 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal colicD056844EFO_1001412N231213
AnalgesiaD000698112
Acute painD059787R52112
AppendicitisD001064EFO_0007149K3722
Abdominal painD015746R10.922
Back painD001416HP_0003418M5422
Allergic conjunctivitisD003233EFO_0007141H10.4411
Allergic rhinitis seasonalD006255EFO_0003956J3011
NephrolithiasisD053040N20.011
EmergenciesD00463011
Show 4 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PulpitisD011671EFO_1001139K04.0415
Kidney calculiD007669EFO_0004253N20.01113
Kidney diseasesD007674EFO_0003086N0811
UrolithiasisD052878N20-N2311
Shoulder impingement syndromeD019534EFO_1001178M75.411
HemiarthroplastyD06278511
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients77
Cerebral arterial diseasesD002539EFO_100085911
Allergic rhinitisD065631J30.911
MammaplastyD01646211
PharmacokineticsD01059911
Blood pressureD001794EFO_000432511
InflammationD00724911
Pancreatic ductal carcinomaD02144111
Pancreatic neoplasmsD010190EFO_0003860C2511
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pathologic dilatationD00410822
KeratoconusD007640EFO_0004223H18.622
RegenerationD01203822
Knee osteoarthritisD020370EFO_0004616M1722
Retinal vein occlusionD012170EFO_1001157H34.8111
Macular degenerationD008268EFO_0001365H35.3011
Head and neck neoplasmsD00625811
Ankle fracturesD064386S82.511
BunionD000071378M21.6111
Hammer toe syndromeD037801EFO_1001336M21.5311
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLANSOPRAZOLE
INNlansoprazole
Description
Lansoprazole is a member of benzimidazoles, a member of pyridines and a sulfoxide. It has a role as an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor and an anti-ulcer drug.
Classification
Small molecule
Drug classantiulcer agents (benzimidazole derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1
Identifiers
PDB
CAS-ID103577-45-3
RxCUI17128
ChEMBL IDCHEMBL480
ChEBI ID6375
PubChem CID3883
DrugBankDB00448
UNII ID0K5C5T2QPG (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 7,209 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6,107 adverse events reported
View more details